UA64716C2 - Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells - Google Patents

Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells Download PDF

Info

Publication number: UA64716C2
Authority: UA; Ukraine
Prior art keywords: group; general formula; compounds; hydroxylamine; piperidinyl
Prior art date: 1996-08-09

Application number

UA99020697A

Other languages

English (en)

Ukrainian (uk)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-09

Filing date

1997-06-08

Publication date

2004-03-15

1996-08-09 Priority claimed from HU9602204A external-priority patent/HUP9602204D0/hu

1997-06-08 Application filed filed Critical

1997-08-04 Priority claimed from HU9701349A external-priority patent/HUP9701349A1/hu

2004-03-15 Publication of UA64716C2 publication Critical patent/UA64716C2/uk

Links

210000003556 vascular endothelial cell Anatomy 0.000 title abstract description 7
230000004064 dysfunction Effects 0.000 title abstract description 4
238000002560 therapeutic procedure Methods 0.000 title abstract description 3
230000002265 prevention Effects 0.000 title abstract 2
239000003814 drug Substances 0.000 title description 12
150000001875 compounds Chemical class 0.000 claims abstract description 131
125000000217 alkyl group Chemical group 0.000 claims abstract description 28
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 25
150000002443 hydroxylamines Chemical class 0.000 claims abstract description 25
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 24
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 20
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 18
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 15
125000001424 substituent group Chemical group 0.000 claims abstract description 14
125000005843 halogen group Chemical group 0.000 claims abstract description 11
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 10
125000002252 acyl group Chemical group 0.000 claims abstract description 9
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 9
125000004423 acyloxy group Chemical group 0.000 claims abstract description 6
125000001188 haloalkyl group Chemical group 0.000 claims abstract description 6
125000001072 heteroaryl group Chemical group 0.000 claims abstract description 6
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 5
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims abstract description 5
125000004122 cyclic group Chemical group 0.000 claims abstract description 5
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 5
125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 5
229910052760 oxygen Inorganic materials 0.000 claims abstract description 5
239000001301 oxygen Substances 0.000 claims abstract description 5
125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 5
229920006395 saturated elastomer Polymers 0.000 claims abstract description 5
150000004668 long chain fatty acids Chemical class 0.000 claims abstract 3
238000011282 treatment Methods 0.000 claims description 27
238000000034 method Methods 0.000 claims description 22
IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 17
210000002889 endothelial cell Anatomy 0.000 claims description 14
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 12
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 11
230000006378 damage Effects 0.000 claims description 10
-1 2-benzoyloxy-3-(1-piperidinyl)propoxy Chemical group 0.000 claims description 9
239000004202 carbamide Substances 0.000 claims description 7
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
230000006806 disease prevention Effects 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 5
229910052717 sulfur Inorganic materials 0.000 claims description 4
239000011593 sulfur Substances 0.000 claims description 4
QWVRTSZDKPRPDF-UHFFFAOYSA-N 5-(piperidin-1-ylmethyl)-3-pyridin-3-yl-5,6-dihydro-2h-1,2,4-oxadiazine Chemical group C1CCCCN1CC(N=1)CONC=1C1=CC=CN=C1 QWVRTSZDKPRPDF-UHFFFAOYSA-N 0.000 claims description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
XEKAUTDWPYQNFU-UHFFFAOYSA-N chlorane Chemical compound Cl.Cl.Cl XEKAUTDWPYQNFU-UHFFFAOYSA-N 0.000 claims description 3
229940126601 medicinal product Drugs 0.000 claims description 3
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
241000269435 Rana <genus> Species 0.000 claims 1
125000004429 atom Chemical group 0.000 claims 1
229910052799 carbon Inorganic materials 0.000 claims 1
201000010099 disease Diseases 0.000 abstract description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
239000008194 pharmaceutical composition Substances 0.000 abstract description 3
239000005864 Sulphur Substances 0.000 abstract 1
239000000243 solution Substances 0.000 description 31
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
239000000203 mixture Substances 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
210000004027 cell Anatomy 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
206010020772 Hypertension Diseases 0.000 description 11
241000700159 Rattus Species 0.000 description 11
229940079593 drug Drugs 0.000 description 10
210000003462 vein Anatomy 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
241001465754 Metazoa Species 0.000 description 9
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
239000007788 liquid Substances 0.000 description 8
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 7
210000002376 aorta thoracic Anatomy 0.000 description 7
230000000694 effects Effects 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
230000008929 regeneration Effects 0.000 description 7
238000011069 regeneration method Methods 0.000 description 7
238000003756 stirring Methods 0.000 description 7
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
239000013543 active substance Substances 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
210000003038 endothelium Anatomy 0.000 description 6
230000001631 hypertensive effect Effects 0.000 description 6
230000005012 migration Effects 0.000 description 6
238000013508 migration Methods 0.000 description 6
230000000877 morphologic effect Effects 0.000 description 6
239000007858 starting material Substances 0.000 description 6
229960001722 verapamil Drugs 0.000 description 6
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 5
230000008602 contraction Effects 0.000 description 5
239000000047 product Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
208000018262 Peripheral vascular disease Diseases 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
208000007536 Thrombosis Diseases 0.000 description 4
239000002253 acid Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004351 coronary vessel Anatomy 0.000 description 4
230000002526 effect on cardiovascular system Effects 0.000 description 4
230000003511 endothelial effect Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
210000002216 heart Anatomy 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
125000004076 pyridyl group Chemical group 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
230000010410 reperfusion Effects 0.000 description 4
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
239000002904 solvent Substances 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
201000001320 Atherosclerosis Diseases 0.000 description 3
208000024172 Cardiovascular disease Diseases 0.000 description 3
206010011086 Coronary artery occlusion Diseases 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
206010048554 Endothelial dysfunction Diseases 0.000 description 3
206010061216 Infarction Diseases 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
239000002775 capsule Substances 0.000 description 3
208000026106 cerebrovascular disease Diseases 0.000 description 3
239000003610 charcoal Substances 0.000 description 3
210000000038 chest Anatomy 0.000 description 3
230000008694 endothelial dysfunction Effects 0.000 description 3
230000007574 infarction Effects 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
210000005240 left ventricle Anatomy 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
208000010125 myocardial infarction Diseases 0.000 description 3
208000031225 myocardial ischemia Diseases 0.000 description 3
239000012044 organic layer Substances 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000002504 physiological saline solution Substances 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
230000001172 regenerating effect Effects 0.000 description 3
WBVFUFJAYLHDBI-UHFFFAOYSA-N 1-chloropropan-1-amine Chemical class CCC(N)Cl WBVFUFJAYLHDBI-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
239000004593 Epoxy Substances 0.000 description 2
208000033892 Hyperhomocysteinemia Diseases 0.000 description 2
102000007330 LDL Lipoproteins Human genes 0.000 description 2
108010007622 LDL Lipoproteins Proteins 0.000 description 2
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
229960004373 acetylcholine Drugs 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
239000003708 ampul Substances 0.000 description 2
230000003257 anti-anginal effect Effects 0.000 description 2
230000002253 anti-ischaemic effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
201000009101 diabetic angiopathy Diseases 0.000 description 2
201000002249 diabetic peripheral angiopathy Diseases 0.000 description 2
238000006193 diazotization reaction Methods 0.000 description 2
230000008753 endothelial function Effects 0.000 description 2
210000000497 foam cell Anatomy 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
230000000004 hemodynamic effect Effects 0.000 description 2
ARBOVOVUTSQWSS-UHFFFAOYSA-N hexadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCC(Cl)=O ARBOVOVUTSQWSS-UHFFFAOYSA-N 0.000 description 2
ANJPRQPHZGHVQB-UHFFFAOYSA-N hexyl isocyanate Chemical compound CCCCCCN=C=O ANJPRQPHZGHVQB-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
230000003225 hyperhomocysteinemia Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
239000011976 maleic acid Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
210000004165 myocardium Anatomy 0.000 description 2
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
229940127557 pharmaceutical product Drugs 0.000 description 2
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
230000008569 process Effects 0.000 description 2
230000001698 pyrogenic effect Effects 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
239000013558 reference substance Substances 0.000 description 2
238000011160 research Methods 0.000 description 2
208000037803 restenosis Diseases 0.000 description 2
239000002356 single layer Substances 0.000 description 2
235000010288 sodium nitrite Nutrition 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 2
125000001544 thienyl group Chemical group 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
210000003606 umbilical vein Anatomy 0.000 description 2
230000002792 vascular Effects 0.000 description 2
FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical class OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
101800000734 Angiotensin-1 Proteins 0.000 description 1
102400000344 Angiotensin-1 Human genes 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
101100346155 Caenorhabditis elegans oma-2 gene Proteins 0.000 description 1
206010008089 Cerebral artery occlusion Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010011091 Coronary artery thrombosis Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
238000012270 DNA recombination Methods 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
241000282412 Homo Species 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
101100049053 Mus musculus Vash1 gene Proteins 0.000 description 1
208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
241001553014 Myrsine salicina Species 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
208000001435 Thromboembolism Diseases 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
206010047141 Vasodilatation Diseases 0.000 description 1
206010047163 Vasospasm Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
238000007259 addition reaction Methods 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
206010002906 aortic stenosis Diseases 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
230000003851 biochemical process Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000012267 brine Substances 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000007766 cera flava Substances 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
208000002528 coronary thrombosis Diseases 0.000 description 1
239000013078 crystal Substances 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000001120 cytoprotective effect Effects 0.000 description 1
230000008260 defense mechanism Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
125000004663 dialkyl amino group Chemical group 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
208000030172 endocrine system disease Diseases 0.000 description 1
ZUBDGKVDJUIMQQ-ZTNLKOGPSA-N endothelin i Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-ZTNLKOGPSA-N 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
229910052730 francium Inorganic materials 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
239000003906 humectant Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000037189 immune system physiology Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000010410 layer Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229960005192 methoxamine Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
230000001617 migratory effect Effects 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
SBGBSARAGZEWGI-UHFFFAOYSA-N n'-hydroxy-3-(trifluoromethyl)benzenecarboximidamide Chemical compound ON=C(N)C1=CC=CC(C(F)(F)F)=C1 SBGBSARAGZEWGI-UHFFFAOYSA-N 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
229940105631 nembutal Drugs 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
FSVCQIDHPKZJSO-UHFFFAOYSA-L nitro blue tetrazolium dichloride Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 FSVCQIDHPKZJSO-UHFFFAOYSA-L 0.000 description 1
JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
125000006501 nitrophenyl group Chemical group 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
MZNXUBVGQOSWEJ-UHFFFAOYSA-N o-(3-piperidin-1-ylpropyl)hydroxylamine Chemical compound NOCCCN1CCCCC1 MZNXUBVGQOSWEJ-UHFFFAOYSA-N 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
229910000489 osmium tetroxide Inorganic materials 0.000 description 1
239000012285 osmium tetroxide Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
229960003912 probucol Drugs 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
239000001294 propane Substances 0.000 description 1
239000011241 protective layer Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
230000000250 revascularization Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000006798 ring closing metathesis reaction Methods 0.000 description 1
239000013049 sediment Substances 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000010959 steel Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000002344 surface layer Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000002885 thrombogenetic effect Effects 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
229910052718 tin Inorganic materials 0.000 description 1
229960000187 tissue plasminogen activator Drugs 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000001665 trituration Methods 0.000 description 1
210000005167 vascular cell Anatomy 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Plural Heterocyclic Compounds (AREA)

UA99020697A 1996-08-09 1997-06-08 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells UA64716C2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
HU9602204A HUP9602204D0 (en)	1996-08-09	1996-08-09	Pharmaceutical compositions for treating diseases connected with the disfunction of the vascular endothelial cells
HU9701349A HUP9701349A1 (hu)	1997-08-04	1997-08-04	Gyógyászati készítmények a vaszkuláris endoteliális sejtek rendellenes működésével összefüggő betegségek gyógyítására vagy megelőzésére
PCT/HU1997/000044 WO1998006400A2 (en)	1996-08-09	1997-08-06	Pharmaceutical products for curing and preventing illnesses connected with the malfunction of vascular endothelial cells

Publications (1)

Publication Number	Publication Date
UA64716C2 true UA64716C2 (en)	2004-03-15

Family

ID=90014231

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA99020697A UA64716C2 (en)	1996-08-09	1997-06-08	Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells

Country Status (19)

Country	Link
US (1)	US6143741A (sr)
EP (1)	EP0966283B1 (sr)
JP (1)	JP2001504446A (sr)
AT (1)	ATE329592T1 (sr)
AU (1)	AU739614B2 (sr)
BG (1)	BG64456B1 (sr)
CA (1)	CA2262997C (sr)
CZ (1)	CZ298542B6 (sr)
DE (1)	DE69736130T2 (sr)
DK (1)	DK0966283T3 (sr)
EE (1)	EE04044B1 (sr)
ES (1)	ES2267148T3 (sr)
IL (1)	IL128256A (sr)
NO (1)	NO325109B1 (sr)
PT (1)	PT966283E (sr)
RS (1)	RS49719B (sr)
SK (1)	SK284301B6 (sr)
UA (1)	UA64716C2 (sr)
WO (1)	WO1998006400A2 (sr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU9701081D0 (en)	1997-06-23	1997-08-28	Gene Research Lab Inc N	Pharmaceutical composition of antitumoral activity
HU226617B1 (en) *	1998-12-14	2009-04-28	Cytrx Corp	Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient
HUP9900475D0 (en) *	1999-02-26	1999-04-28	Biorex Kutato Fejlesztoe Kft	O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
JP2005514418A (ja) *	2002-01-11	2005-05-19	ビオレックスクタトーエスフェイレストェーアールテー．	カルボキサミジン誘導体及び血管疾患の治療におけるそれらの使用
HUP0303584A3 (en)	2003-10-30	2009-12-28	Cytrx Corp	Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
WO2008039514A1 (en) *	2006-09-26	2008-04-03	Cytrx Corporation	Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration
MX2009005798A (es) *	2006-12-01	2009-08-12	Cytrx Corp	Recuperacion de apoplejia.
TW200901958A (en) *	2007-05-04	2009-01-16	Cytrx Corp	Diabetic wound healing
JP5429865B2 (ja) *	2009-09-15	2014-02-26	学校法人日本大学	生体外創傷治癒試験用用具または創傷作製方法
HUP1100535A2 (en) *	2011-09-26	2013-04-29	Bracelia Invest Ltd	Pharmaceutical composition for enhancement of stem cell treatment
WO2016201168A1 (en) *	2015-06-10	2016-12-15	Forum Pharmceuticals Inc.	Oxadiazine compounds and methods of use thereof
KR20230128462A (ko)	2020-11-19	2023-09-05	제브라 덴마크 에이/에스	아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4187220A (en) *	1977-08-30	1980-02-05	Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T.	New O-(3-amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU207988B (en) *	1988-10-20	1993-07-28	Biorex Kutato Fejlesztoe Kft	Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
GB9017351D0 (en) *	1990-08-08	1990-09-19	Wellcome Found	Medicaments for treatment of atherosclerosis
US5919796A (en) *	1994-05-06	1999-07-06	Biorex Kutato Es Fejleszto Rt.	Hydroximic acid derivatives, pharmaceutical compositions containing them, and processes for preparing the same
HU218480B (hu) *	1995-06-15	2000-09-28	BIOREX Kutató és Fejlesztő Rt.	Hidroxilaminszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HU222994B1 (hu) *	1995-11-02	2004-01-28	BIOREX Kutató és Fejlesztő Rt.	Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására

1997
- 1997-06-08 UA UA99020697A patent/UA64716C2/uk unknown
- 1997-08-06 CZ CZ0043599A patent/CZ298542B6/cs not_active IP Right Cessation
- 1997-08-06 AT AT97933813T patent/ATE329592T1/de active
- 1997-08-06 EE EEP199900044A patent/EE04044B1/xx not_active IP Right Cessation
- 1997-08-06 JP JP50952798A patent/JP2001504446A/ja not_active Ceased
- 1997-08-06 ES ES97933813T patent/ES2267148T3/es not_active Expired - Lifetime
- 1997-08-06 SK SK154-99A patent/SK284301B6/sk not_active IP Right Cessation
- 1997-08-06 US US09/230,941 patent/US6143741A/en not_active Expired - Fee Related
- 1997-08-06 AU AU37049/97A patent/AU739614B2/en not_active Ceased
- 1997-08-06 CA CA002262997A patent/CA2262997C/en not_active Expired - Fee Related
- 1997-08-06 RS YUP-51/99A patent/RS49719B/sr unknown
- 1997-08-06 IL IL12825697A patent/IL128256A/en not_active IP Right Cessation
- 1997-08-06 DK DK97933813T patent/DK0966283T3/da active
- 1997-08-06 PT PT97933813T patent/PT966283E/pt unknown
- 1997-08-06 WO PCT/HU1997/000044 patent/WO1998006400A2/en not_active Ceased
- 1997-08-06 EP EP97933813A patent/EP0966283B1/en not_active Expired - Lifetime
- 1997-08-06 DE DE69736130T patent/DE69736130T2/de not_active Expired - Lifetime
1999
- 1999-02-05 NO NO19990547A patent/NO325109B1/no not_active IP Right Cessation
- 1999-02-22 BG BG103194A patent/BG64456B1/bg unknown

Also Published As

Publication number	Publication date
ATE329592T1 (de)	2006-07-15
NO990547D0 (no)	1999-02-05
RS49719B (sr)	2007-12-31
EE04044B1 (et)	2003-06-16
DE69736130D1 (de)	2006-07-27
BG103194A (en)	1999-09-30
SK15499A3 (en)	2000-02-14
YU5199A (sh)	2000-10-30
EP0966283A2 (en)	1999-12-29
NO990547L (no)	1999-03-25
NO325109B1 (no)	2008-02-04
DE69736130T2 (de)	2007-01-04
CZ43599A3 (cs)	1999-07-14
ES2267148T3 (es)	2007-03-01
CZ298542B6 (cs)	2007-10-31
SK284301B6 (sk)	2005-01-03
IL128256A (en)	2004-05-12
WO1998006400A2 (en)	1998-02-19
BG64456B1 (bg)	2005-03-31
HK1025506A1 (en)	2000-11-17
US6143741A (en)	2000-11-07
AU3704997A (en)	1998-03-06
WO1998006400A3 (en)	1998-03-26
IL128256A0 (en)	2000-02-17
JP2001504446A (ja)	2001-04-03
EE9900044A (et)	1999-08-16
DK0966283T3 (da)	2006-10-09
CA2262997A1 (en)	1998-02-19
PT966283E (pt)	2006-08-31
EP0966283B1 (en)	2006-06-14
AU739614B2 (en)	2001-10-18
CA2262997C (en)	2008-07-29

Publication	Publication Date	Title
JP4531865B2 (ja)	2010-08-25	分子シャペロン産生を増強するのに有用なヒドロキシルアミン誘導体およびそれの調製
UA64716C2 (en)	2004-03-15	Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
KR20110137941A (ko)	2011-12-26	신규한 티오우레아 또는 우레아 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 ａｉｄｓ 예방 또는 치료용 약학 조성물
US6232331B1 (en)	2001-05-15	Benzofuroxan derivatives, their therapeutic uses and pharmaceutical compositions
RU2195273C2 (ru)	2002-12-27	Фармацевтические продукты для лечения и профилактики заболеваний, появляющихся в результате повреждения эндотелиальных клеток сосудов
US5342838A (en)	1994-08-30	Phenolic thioetheramides
JP2025503165A (ja)	2025-01-30	心不全（ｈｆ）を予防又は処置するための組成物
CN108774220A (zh)	2018-11-09	用于治疗心肌缺血的化合物及其应用
HK1025506B (en)	2007-01-05	Pharmaceutical products for curing and preventing diseases resulting from the damaging of the vascular endothelial cells
CS228104B2 (en)	1984-05-14	Preparation of esters of nitric acid and n-/2-hydroxyethyl/nicotinamides
HUT75093A (en)	1997-04-28	New anti-radical pharmaceutical compositions and process for producing them
PL190673B1 (pl)	2005-12-30	Zastosowanie pochodnych hydroksyloaminy
IE48587B1 (en)	1985-03-20	Urea derivatives